Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) EBITDA Margin (2021)

Atea Pharmaceuticals has reported EBITDA Margin over the past 1 years, most recently at 60.95% for Q4 2021.

  • Quarterly results put EBITDA Margin at 60.95% for Q4 2021, changed N/A from a year ago — trailing twelve months through Sep 2022 was 18.11% (down 187.0% YoY), and the annual figure for FY2021 was 34.49%, up 5700.0%.
  • EBITDA Margin for Q4 2021 was 60.95% at Atea Pharmaceuticals, up from 85.93% in the prior quarter.
  • Over the last five years, EBITDA Margin for AVIR hit a ceiling of 60.95% in Q4 2021 and a floor of 85.93% in Q3 2021.